LG-2527

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
LG-2527
Clinical data
Drug classProgestin; Progestogen

LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]

References[edit]

  1. ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.